Palivizumab 100mg powder and solvent for solution for injection vials
Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV).
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Palivizumab
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Palivizumab
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Palivizumab
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
18-20 days
Mechanism
Palivizumab binds to the fusion glycoprotein of RSV.
Food interactions
None known
Human targets
8 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Half-life
18-20 days
Metabolism
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 393 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils
PMID:11711607 PMID:21768335 PMID:22023369 PMID:24412922 PMID:25786175 PMID:25816339 PMID:28652325 PMID:8609432 PMID:9242542
Mediates IgG effector functions on natural killer (NK) cells.
Binds antigen-IgG complexes generated upon infection and triggers NK cell-dependent cytokine production and degranulation to limit viral load and propagation. Involved in the generation of memory-like adaptive NK cells capable to produce high amounts of IFNG and to efficiently eliminate virus-infected cells via ADCC .
PMID:24412922 PMID:25786175
Regulates NK cell survival and proliferation, in particular by preventing NK cell progenitor apoptosis .
PMID:29967280 PMID:9916693
Fc-binding subunit that associates with CD247 and/or FCER1G adapters to form functional signaling complexes. Following the engagement of antigen-IgG complexes, triggers phosphorylation of immunoreceptor tyrosine-based activation motif (ITAM)-containing adapters with subsequent activation of phosphatidylinositol 3-kinase signaling and sustained elevation of intracellular calcium that ultimately drive NK cell activation.
The ITAM-dependent signaling coupled to receptor phosphorylation by PKC mediates robust intracellular calcium flux that leads to production of pro-inflammatory cytokines, whereas in the absence of receptor phosphorylation it mainly activates phosphatidylinositol 3-kinase signaling leading to cell degranulation .
PMID:1825220 PMID:23024279 PMID:2532305
Costimulates NK cells and trigger lysis of target cells independently of IgG binding .
PMID:10318937 PMID:23006327
Mediates the antitumor activities of therapeutic antibodies. Upon ligation on monocytes triggers TNFA-dependent ADCC of IgG-coated tumor cells .
PMID:27670158
Mediates enhanced ADCC in response to afucosylated IgGs PMID:34485821
PMID:17996945 PMID:19473974 PMID:29449492
C1R catalyzes the first enzymatic step in the classical complement pathway: it is activated by the C1Q subcomplex of the C1 complex, which associates with IgG or IgM immunoglobulins complexed with antigens to form antigen-antibody complexes on the surface of pathogens .
PMID:29449492 PMID:34155115
Immunoglobulin-binding promotes the autocatalytic cleavage and activation of C1R .
PMID:11445589 PMID:11673533 PMID:17996945 PMID:20178990 PMID:6254570 PMID:6271784
Activated C1R then cleaves and activates C1S, the second protease of the classical complement pathway .
PMID:11445589 PMID:11673533 PMID:6271784
It is unclear if C1R activates C1S within single, strained C1 complexes or between neighboring C1 complexes on surfaces PMID:28104818 PMID:29311313 PMID:29449492
PMID:12847249 PMID:19006321 PMID:24626930 PMID:29449492 PMID:3258649 PMID:34155115 PMID:6249812 PMID:6776418
The classical complement pathway is initiated by the C1Q subcomplex of the C1 complex, which specifically binds IgG or IgM immunoglobulins complexed with antigens, forming antigen-antibody complexes on the surface of pathogens: C1QA, together with C1QB and C1QC, specifically recognizes and binds the Fc regions of IgG or IgM via its C1q domain .
PMID:12847249 PMID:19006321 PMID:24626930 PMID:29449492 PMID:3258649 PMID:6776418
Immunoglobulin-binding activates the proenzyme C1R, which cleaves C1S, initiating the proteolytic cascade of the complement system .
PMID:29449492
The C1Q subcomplex is activated by a hexamer of IgG complexed with antigens, while it is activated by a pentameric IgM .
PMID:19706439 PMID:24626930 PMID:29449492
The C1Q subcomplex also recognizes and binds phosphatidylserine exposed on the surface of cells undergoing programmed cell death, possibly promoting activation of the complement system PMID:18250442
ATC J06BD01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Palivizumab
Additional database identifiers
Drugs Product Database (DPD)
12770
GenBank Gene Database
D00334
GenBank Protein Database
222565
UniProt Accession
FUS_HRSV1
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3620
GenAtlas
FCGR3B
GeneCards
FCGR3B
GenBank Gene Database
X16863
GenBank Protein Database
31322
UniProt Accession
FCG3B_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3619
GenAtlas
FCGR3A
GeneCards
FCGR3A
GenBank Gene Database
X52645
GenBank Protein Database
31324
Guide to Pharmacology
3017
UniProt Accession
FCG3A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3613
GenAtlas
FCGR1A
GeneCards
FCGR1A
GenBank Gene Database
X14356
GenBank Protein Database
31332
UniProt Accession
FCGR1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1246
GenAtlas
C1R
GeneCards
C1R
GenBank Gene Database
X04701
GenBank Protein Database
29539
Guide to Pharmacology
2334
UniProt Accession
C1R_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1241
GenAtlas
C1QA
GeneCards
C1QA
GenBank Gene Database
AF135157
GenBank Protein Database
4894854
UniProt Accession
C1QA_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1242
GenAtlas
C1QB
GeneCards
C1QB
GenBank Gene Database
X03084
GenBank Protein Database
573114
UniProt Accession
C1QB_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1245
GenAtlas
C1QC
GeneCards
C1QC
GenBank Gene Database
AF087892
GenBank Protein Database
33150626
UniProt Accession
C1QC_HUMAN
UniProt Accession
FUS_HRSVA
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3618
GenAtlas
FCGR2B
GeneCards
FCGR2B
GenBank Gene Database
U87560
GenBank Protein Database
4099445
UniProt Accession
FCG2B_HUMAN
Patent information
All patents expired, 1 expired
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: